6533b824fe1ef96bd1281323
RESEARCH PRODUCT
Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and Austria
Günter HenzeGabriele CalaminusMartin ZimmermannWilli WoessmannA Von StackelbergHelmut GadnerHeribert JuergensChristine Mauz-koerholzGeorg MannNorbert GrafMartin SchrappeBirgit BurkhardtBirgit BurkhardtStefan RutkowskiClaudia RossigUta DirksenDirk ReinhardtGünther SchellongPeter KaatschAnja MoerickeU. CreutzigFrank BertholdStefan S. Bielacksubject
medicine.medical_specialtyPediatricsbusiness.industryChildhood cancerHematologyPediatric cancerClinical trialOncologyInterimScale (social sciences)Pediatrics Perinatology and Child HealthTreatment intensitymedicineOverall survivalTumor boardIntensive care medicinebusinessdescription
In Germany and Austria, more than 90% of pediatric cancer patients are enrolled into nationwide disease-specific first-line clinical trials or interim registries. Essential components are a pediatric cancer registry and centralized reference laboratories, imaging review, and tumor board assistance. The five-year overall survival rate in countries where such infrastructures are established has improved from 80% since 1995. Today, treatment intensity is tailored to the individual patient's risk to provide the highest chances of survival while minimizing deleterious late effects. Multicenter clinical trials are internationalized and serve as platforms for further improvements by novel drugs and biologicals.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2013-06-05 | Pediatric Blood & Cancer |